Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/4/2018
SIETES contiene 92261 citas

 
 
 1 a 20 de 1175 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Joseph A. Panel recommends FDA approval of epilepsy drug derived from marijuana. DIA Daily 2018:1. [Ref.ID 102518]
3.Tiene citas relacionadas Cita con resumen
Varadkar S. Cannabidiol for drop seizures in Lennox-Gastaut syndrome. Lancet 2018;391:1006-7. [Ref.ID 102474]
4. Cita con resumen
Pennell PB. Antiepileptic drugs in pregnancy — Quick decisions with long-term consequences. JAMA Neurology 2018:1. [Ref.ID 102464]
5. Cita con resumen
Elkjær LS, Bech BH, Sun Y, Laursen TM, Christensen J. Association between prenatal valproate exposure and performance on standardized language and mathematics tests in school-aged children. JAMA Neurology 2018:1. [Ref.ID 102463]
6.Tiene citas relacionadas Cita con resumen
Thiele EA, French ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K, on behalf of the GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018;391:24 de enero. [Ref.ID 102450]
7.
Whitlock J. Cannabis-derived drug granted priority review. San Diego Business Journal 2018:2 de enero. [Ref.ID 102441]
8. Cita con resumen
Johansen ME. Gabapentinoid use in the United States 2002 through 2015. JAMA Intern Med 2018:2 de enero. [Ref.ID 102440]
9.Tiene citas relacionadas Cita con resumen
Devinsky O, Cross JH, Wright S. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;377:699-700. [Ref.ID 102019]
10.Tiene citas relacionadas Cita con resumen
Tang R, Fang F. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;377:699. [Ref.ID 102018]
11. Cita con resumen
Anónimo. Brivaracétam et épilepsie partielle. Prescrire 2017;37:412-3. [Ref.ID 101999]
12. Cita con resumen
Russo EB. Cannabidiol claims and misconceptions. Trends Pharmacol Sci 2017;38:198-201. [Ref.ID 101988]
13.
Anónimo. Brivaracetam for epilepsy. Australian Prescriber 2017;40:112-3. [Ref.ID 101611]
14.Tiene citas relacionadas Cita con resumen
Berkovic SF. Cannabinoids for epilepsy — Real data, at last. N Engl J Med 2017;376:2075-6. [Ref.ID 101596]
15.Tiene citas relacionadas Cita con resumen
Devinsky O, Cross JH, Laux L, Marsh E, Nabbout R, Scheffer IE, Thiele EA, Wright S, for the Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;376:2011-20. [Ref.ID 101595]
16. Cita con resumen
Bradford AC, Bradford WD. Medical marijuana laws may be associated with a decline in the number of prescriptions for Medicaid enrollees. Health Affairs 2017;36:1 de mayo. [Ref.ID 101570]
17. Cita con resumen
Anónimo. Malformations congénitales chez les enfants exposés in utero au valproate et aux autres traitements de l’épilepsie et des troubles bipolaires - Communiqué. Agence Nationale de Sécurité des Médicaments et des Produits de Santé 2017:20 de abril. [Ref.ID 101537]
18. Cita con resumen
Anónimo. Various states approve recreational, medical marijuana use. DIA Daily 2016:7. [Ref.ID 100907]
19. Cita con resumen
Anónimo. Pfizer loses UK appeal over pregabalin patent dispute. DIA Daily 2016:1. [Ref.ID 100808]
20. Cita con resumen
Baftiu A, Landmark CJ, Rusten IR, Feet SA, Johannessen SI, Larsson PG. Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders - A pharmacoepidemiological study and clinical implications. Eur J Clin Pharmacol 2016;72:1245-54. [Ref.ID 100799]
Seleccionar todas
 
 1 a 20 de 1175 siguiente >>